‌

US Patent 11945880 Heterodimeric antibodies that bind CD3 and tumor antigens

Patent 11945880 was granted and assigned to Xencor on April, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

John Desjarlais0

Umesh Muchhal0

Rumana Rashid0

Gregory Moore0

Seung Chu0

Sung-Hyung Lee0

Matthew J. Bernett0

Date of Patent

April 2, 2024

0

Patent Application Number

175423420

Date Filed

December 3, 2021

0

Patent Citations

US Patent 7276497 Cytotoxic agents comprising new maytansinoids

0

US Patent 6884869 Pentapeptide compounds and uses related thereto

0

US Patent 6989452 Disulfide prodrugs and linkers and stabilizers useful therefor

0

US Patent 7087600 Peptidyl prodrugs and linkers and stabilizers useful therefor

0

US Patent 7112324 CD 19×CD3 specific polypeptides and uses thereof

0

US Patent 7129261 Cytotoxic agents

0

US Patent 8637641 Antibodies with modified isoelectric points

0

US Patent 8946387 FcγRIIB specific antibodies and methods of use thereof

0

...

Patent Primary Examiner

0

CPC Code

0

Patent abstract

The present invention is directed to novel heterodimeric antibodies.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11945880 Heterodimeric antibodies that bind CD3 and tumor antigens

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.